DIAGNOSTIC ACCURACY OF CONTRAST ENHANCED CT SCAN IN DIAGNOSING BRONCHOGENIC CARCINOMA, TAKING HISTOPATHOLOGY AS GOLD STANDARD

Gul sanam, Anashia kayani, Zafar Amin, Raheel khan, Najwa Zahoor, Tehmina irshad, zainab shehzadi

Abstract


Objectives: To determine the diagnostic accuracy of contrast enhanced CT scan in diagnosing bronchogenic carcinoma, taking histopathology as gold standard.

Study design: Cross-sectional validation study.

Setting: Department of Radiology, Armed Forces Institute of Radiology, Rawalpindi from 8th December 2020 to 7th June 2021

Methodology: A total of 148 patients with suspected bronchogenic carcinoma between 20-70 years of age were included. Patients with already taking treatment, CRF and h/o allergy to contrast agent were excluded. Then CT was performed on Toshiba Asteion Multi Slice Scanner with I/V contrast. CT scan findings were interpreted by one consultant radiologist (at least 5 years of experience) and was looked for bronchogenic carcinoma as per-operational definition. All patients were then undergone CT guided transthoracic biopsy of pulmonary lesions by the relevant interventional radiologist and specimen was sent to institutional pathology laboratory for histopathology.

Results: Overall sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of contrast enhanced CT scan in diagnosing bronchogenic carcinoma, taking histopathology as gold standard was 94.32%, 91.67%, 94.32%, 91.67% and 93.24% respectively.

Conclusion: This study concluded that the diagnostic accuracy of contrast enhanced CT scan in diagnosing bronchogenic carcinoma is very high. 

Keywords: bronchogenic carcinoma, computed tomography, sensitivity.


Full Text:

PDF

References


Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

Goldstraw P, Cansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39-51.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of american pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018;142(3):321-46.

Gao F, Li M, Sun Y, Xiao L, Hua Y. Diagnostic value of contrast-enhanced CT scans in identifying lung adenocarcinomas manifesting as GGNs (ground glass nodules). Medicine (Baltimore). 2017;96(43):e7742.

Khalil A, Majlath M, Gounant V, Hess A, Laissy JP, Debray MP. Contribution of magnetic resonance imaging in lung cancer imaging. Diagno Intervent Imag. 2016;97(10):991-1002.

Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, et al. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. Chest. 2018;153(4):954-85.

MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT Images: From the Fleischner Society 2017. Radiol. 2017;284(1):228-43.

Khaliq N, Jesrani A, Mansoor MA, Nazmani WM, Mustansir H. Zaidi and Mahmud R. Diagnostic accuracy of contrast enhanced computed tomography in detecting bronchogenic carcinoma -experience at Liaquat National Hospital, J Dow Uni Health Sci 2017;11(1):18-23.

SEER cancer statistics review, 1975-2008 [homepage on the internet]. Bethesda, MD: National Cancer Institute; 2010. [cited 2011 05/16]. Available from: http://seer.cancer.gov/csr/1975_2008/

Harders SW, Madsen HH, Nellemann HM, Rasmussen TR, Thygesen J, Hager H, et al. Can visual assessment of blood flow patterns by dynamic contrast-enhanced computed tomography distinguish between malignant and benign lung tumors? Acta Radiol Open. 2017 May 30;6(5):2058460117710053–2058460117710053.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. Cancer J Clin. 2005;55;74- 108.

99. Frumkin H, Thun M. Arsenic. Cancer. Cancer J Clinici. 2001:51:254-62.

Khan MB, Mashood AA, Qureshi AA, Ibrar K. Tuberculosis Disease pattern and sputum microscopy yield. Pak J Chest Med. 2005 Dec:11:11-9.

Toyoda Y, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low dose computed tomography. Br J Cancer. 2008;98:1602-7.

Herman SJ, Winton TL, Weisbrod GL, Tower MJ, Mentzer SJ. Mediastinal invasion by bronchogenic carcinoma: CT signs. Radiology 1994;190:841–846.

Glazer HS, Kaiser LR, Anderson DJ, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology 1989;173:37–42.

McLoud TC. CT of bronchogenic carcinoma: indeterminate mediastinal invasion. Radiology 1989;173:15–16.

Izbicki J, Thetter O, Karg O. Accuracy of computed tomographic scan and surgical assessment for staging of bronchial carcinoma. J Thorac Cardiovasc Surg 1992;104:413–420.


Refbacks

  • There are currently no refbacks.


© Copyright PJR 2008-